(PFE) Pfizer - Overview
Stock: Vaccines, Antibiotics, Oncology, Cardiovascular, Biologics
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 8.75% |
| Yield on Cost 5y | 6.17% |
| Yield CAGR 5y | 2.47% |
| Payout Consistency | 97.9% |
| Payout Ratio | 53.8% |
| Risk 5d forecast | |
|---|---|
| Volatility | 25.4% |
| Relative Tail Risk | -5.58% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.17 |
| Alpha | -3.58 |
| Character TTM | |
|---|---|
| Beta | 0.491 |
| Beta Downside | 0.544 |
| Drawdowns 3y | |
|---|---|
| Max DD | 45.25% |
| CAGR/Max DD | -0.23 |
Description: PFE Pfizer January 27, 2026
Pfizer Inc. (NYSE:PFE) discovers, develops, manufactures, markets and distributes a broad portfolio of biopharmaceutical products worldwide, spanning cardiovascular-migraine treatments (Eliquis, Nurtec ODT/Vydura), infectious-disease vaccines (Prevnar, Abrysvo, Trumenba), COVID-19 solutions (Comirnaty, Paxlovid), biosimilars (Xeljanz, Enbrel), and specialty therapies for amyloidosis, hemophilia, endocrine and sickle-cell diseases. The company also operates a contract-manufacturing business and serves a diverse customer base that includes wholesalers, hospitals, pharmacies and government agencies, while maintaining strategic collaborations with firms such as Bristol-Myers Squibb, Astellas, Merck KGaA, BioNTech and AI-focused partner Boltz, PBC.
Key recent metrics: • FY 2023 total revenue was $100.3 billion, down 2 % YoY as COVID-19 product sales fell ≈ $4 billion, while core franchise growth (e.g., Eliquis +5 % and Prevnar +3 %) partially offset the decline. • Q1 2024 adjusted earnings per share (EPS) came in at $1.15, beating consensus by 8 % and reflecting a 12 % YoY increase in R&D efficiency (R&D spend $9.5 billion, 9.5 % of revenue). • The global biopharma sector is projected to grow 6 % CAGR through 2028, driven by aging populations and rising demand for specialty biologics-trends that align with Pfizer’s focus on high-margin immunology and oncology pipelines.
For a deeper, data-driven assessment of Pfizer’s valuation dynamics, you may find the ValueRay platform’s analytical tools useful.
Piotroski VR‑10 (Strict, 0-10) 6.0
| Net Income: 9.82b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.05 > 0.02 and ΔFCF/TA 1.22 > 1.0 |
| NWC/Revenue: 16.45% < 20% (prev 0.02%; Δ 16.43% < -1%) |
| CFO/TA 0.06 > 3% & CFO 13.08b > Net Income 9.82b |
| Net Debt (60.37b) to EBITDA (21.17b): 2.85 < 3 |
| Current Ratio: 1.28 > 1.5 & < 3 |
| Outstanding Shares: last quarter (5.71b) vs 12m ago 0.16% < -2% |
| Gross Margin: 71.19% > 18% (prev 0.59%; Δ 7060 % > 0.5%) |
| Asset Turnover: 29.32% > 50% (prev 27.54%; Δ 1.79% > 0%) |
| Interest Coverage Ratio: 5.36 > 6 (EBITDA TTM 21.17b / Interest Expense TTM 2.70b) |
Altman Z'' 3.70
| A: 0.05 (Total Current Assets 46.92b - Total Current Liabilities 36.60b) / Total Assets 208.73b |
| B: 0.58 (Retained Earnings 121.15b / Total Assets 208.73b) |
| C: 0.07 (EBIT TTM 14.47b / Avg Total Assets 214.10b) |
| D: 0.98 (Book Value of Equity 113.56b / Total Liabilities 115.64b) |
| Altman-Z'' Score: 3.70 = AA |
Beneish M -3.39
| DSRI: 0.78 (Receivables 14.26b/17.69b, Revenue 62.78b/60.43b) |
| GMI: 0.82 (GM 71.19% / 58.73%) |
| AQI: 0.95 (AQ_t 0.68 / AQ_t-1 0.72) |
| SGI: 1.04 (Revenue 62.78b / 60.43b) |
| TATA: -0.02 (NI 9.82b - CFO 13.08b) / TA 208.73b) |
| Beneish M-Score: -3.39 (Cap -4..+1) = AA |
What is the price of PFE shares?
Over the past week, the price has changed by +3.08%, over one month by +7.57%, over three months by +12.62% and over the past year by +5.39%.
Is PFE a buy, sell or hold?
- StrongBuy: 7
- Buy: 2
- Hold: 15
- Sell: 0
- StrongSell: 1
What are the forecasts/targets for the PFE price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 28.8 | 8.9% |
| Analysts Target Price | 28.8 | 8.9% |
| ValueRay Target Price | 28.6 | 8.1% |
PFE Fundamental Data Overview January 31, 2026
P/E Forward = 9.0009
P/S = 2.3536
P/B = 1.5991
P/EG = 3.7725
Revenue TTM = 62.78b USD
EBIT TTM = 14.47b USD
EBITDA TTM = 21.17b USD
Long Term Debt = 56.55b USD (from longTermDebt, last quarter)
Short Term Debt = 4.30b USD (from shortTermDebt, last quarter)
Debt = 61.71b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 60.37b USD (from netDebt column, last quarter)
Enterprise Value = 208.14b USD (147.77b + Debt 61.71b - CCE 1.34b)
Interest Coverage Ratio = 5.36 (Ebit TTM 14.47b / Interest Expense TTM 2.70b)
EV/FCF = 20.06x (Enterprise Value 208.14b / FCF TTM 10.38b)
FCF Yield = 4.99% (FCF TTM 10.38b / Enterprise Value 208.14b)
FCF Margin = 16.53% (FCF TTM 10.38b / Revenue TTM 62.78b)
Net Margin = 15.64% (Net Income TTM 9.82b / Revenue TTM 62.78b)
Gross Margin = 71.19% ((Revenue TTM 62.78b - Cost of Revenue TTM 18.09b) / Revenue TTM)
Gross Margin QoQ = 74.95% (prev 64.29%)
Tobins Q-Ratio = 1.00 (Enterprise Value 208.14b / Total Assets 208.73b)
Interest Expense / Debt = 1.06% (Interest Expense 652.0m / Debt 61.71b)
Taxrate = 21.0% (US default 21%)
NOPAT = 11.43b (EBIT 14.47b * (1 - 21.00%))
Current Ratio = 1.28 (Total Current Assets 46.92b / Total Current Liabilities 36.60b)
Debt / Equity = 0.66 (Debt 61.71b / totalStockholderEquity, last quarter 92.80b)
Debt / EBITDA = 2.85 (Net Debt 60.37b / EBITDA 21.17b)
Debt / FCF = 5.82 (Net Debt 60.37b / FCF TTM 10.38b)
Total Stockholder Equity = 90.01b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.59% (Net Income 9.82b / Total Assets 208.73b)
RoE = 10.91% (Net Income TTM 9.82b / Total Stockholder Equity 90.01b)
RoCE = 9.88% (EBIT 14.47b / Capital Employed (Equity 90.01b + L.T.Debt 56.55b))
RoIC = 7.54% (NOPAT 11.43b / Invested Capital 151.69b)
WACC = 5.70% (E(147.77b)/V(209.48b) * Re(7.73%) + D(61.71b)/V(209.48b) * Rd(1.06%) * (1-Tc(0.21)))
Discount Rate = 7.73% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: 100.0 | Cagr: 0.59%
[DCF Debug] Terminal Value 83.67% ; FCFF base≈9.52b ; Y1≈7.55b ; Y5≈5.04b
Fair Price DCF = 16.66 (EV 155.10b - Net Debt 60.37b = Equity 94.73b / Shares 5.69b; r=5.90% [WACC]; 5y FCF grow -24.64% → 2.90% )
EPS Correlation: -42.60 | EPS CAGR: -5.60% | SUE: 2.45 | # QB: 9
Revenue Correlation: -68.94 | Revenue CAGR: -9.12% | SUE: 0.08 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.75 | Chg30d=-0.017 | Revisions Net=-3 | Analysts=11
EPS next Year (2026-12-31): EPS=2.97 | Chg30d=-0.033 | Revisions Net=-7 | Growth EPS=-4.9% | Growth Revenue=-1.5%